Level of the indication of biologic agents in the 2012 American college of rheumatology recommendations for the treatment of rheumatoid arthritis: Comment on the article by Singh et al

Arthritis Care and Research

Volumn 65, Issue 5, 2013, Pages 832-

  Graudal, Niels ^a   Jürgens, Gesche ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; METHOTREXATE;

HUMAN; LETTER; OUTCOME ASSESSMENT; PROGNOSIS; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT INDICATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY;

EID: 84876697541     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21873     Document Type: Letter

References (6)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
2. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
3. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
4. Graudal N, Jurgens G,. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010; 62: 2852-63.
5. Ma MH, Kingsley GH, Scott DL,. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2010; 49: 91-8.
6. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St. Clair EW, et al, for the TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis trial. Arthritis Rheum 2012; 64: 2824-35.